Speeches and presentations
Search through our archive of speeches and presentations from conferences and events.
Visit our corporate reporting archive for our Annual Reports.
For quarterly results materials visit quarterly results.
12 March 2019
Cowen & Co. 39th Annual Health Care Conference, Boston
Luke Miels, President Global Pharmaceuticals, hosted a fireside chat at the Cowen & Co. 39th Annual Health Care Conference 2019 in Boston on Tuesday 12 March, during which he provided an update on the progress GSK is making in the global pharmaceuticals and vaccines business.
28 February 2019
SVB Leerink Global Healthcare Conference, New York
Brian McNamara, CEO GSK Consumer Healthcare, hosted a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference that took place in New York City on Thursday 28 February during which he provided an update on the Consumer Healthcare business and the formation of a new, world-leading Consumer Healthcare joint venture.
14 February 2019
Guggenheim Healthcare Talks Idea Forum, New York
Axel Hoos, SVP Oncology R&D, hosted a Fireside Chat at the Guggenheim Healthcare Talks Idea Forum - Oncology Day held in New York City on Thursday 14 February during which he provided an update on GSK Oncology R&D progress.
08 January 2019
37th annual JP Morgan Healthcare Conference, San Francisco
Emma Walmsley, CEO, gave a presentation at the 37th annual JP Morgan Healthcare Conference in San Francisco on Tuesday 8 January, providing an overview of GSK’s priorities and the progress the company made during 2018.
19 December 2018
Analyst call on formation of new Consumer Healthcare JV
On Wednesday 19 December 2018, GSK announced an agreement with Pfizer Inc to combine their consumer health businesses into a new world-leading Joint Venture. A call for investors and analysts was hosted by Emma Walmsley, Chief Executive Officer, Brian McNamara, CEO GSK Consumer Healthcare and Simon Dingemans, Chief Financial Officer.
10 December 2018
ViiV Meet the Management, London
David Redfern, Chairman ViiV Healthcare and Deborah Waterhouse, CEO ViiV Healthcare along with members of the ViiV Healthcare leadership team hosted a ViiV Healthcare Investor Event on Monday 10 December in London. The event included presentations from David, Deborah, Dr Kimberly Smith Global Research & Medical Strategy, Eric Dube Head of North America and Dr John Pottage Chief Scientific & Medical Officer and was followed by a Q&A session
05 December 2018
Citi 2018 Global Healthcare Conference, New York
Hal Barron, Chief Scientific Officer and President, R&D hosted a fireside chat at the Citi 2018 Global Healthcare Conference held in New York City on Wednesday 5 December, in which he provided an overview of GSK’s R&D priorities and progress made during 2018.
03 December 2018
Analyst call on agreement to acquire TESARO
On Monday, 3 December 2018, GSK announced an agreement to acquire TESARO, an oncology-focused company based in the US. A call for investors and analysts was hosted by Emma Walmsley, Chief Executive Officer, Simon Dingemans, Chief Financial Officer, Dr Hal Barron, Chief Scientific Officer and President R&D, and Luke Miels, President, GSK Global Pharmaceuticals.
28 November 2018
Evercore ISI HealthConX Conference, Boston
Deborah Waterhouse, CEO, and Dr Kimberly Smith, Head of Global Research and Medical Strategy, ViiV Healthcare, hosted a fireside chat at the Evercore ISI HealthConX Conference held in Boston, Massachusetts on Wednesday 28 November, during which they provided an overview of ViiV’s priorities and progress made during 2018.
23 October 2018
Investor and Analyst call on GSK’165 aGM-CSF data presented at ACR
On Tuesday, 23 October 2018, Dr Hal Barron, Chief Scientific Officer and President R&D and Luke Miels, President, GSK Global Pharmaceuticals hosted an investor conference call following the presentation of efficacy and safety data on GSK3196165, GSK's anti-GM-CSF antibody in development for Rheumatoid Arthritis at the 2018 American College of Rheumatology (ACR). The call also featured participation from an external expert in rheumatology and GSK’s Medicine Development Lead for GSK’165.
